Geode Capital Management, LLC Indaptus Therapeutics, Inc. Transaction History

Geode Capital Management, LLC

$1.24 Trillion
Q1 2025

A detailed history of Geode Capital Management, LLC transactions in Indaptus Therapeutics, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 124,967 shares of INDP stock, worth $46,237. This represents 0.0% of its overall portfolio holdings.

Number of Shares

124,967

Previous 82,118 52.18%

Holding current value

$46,237

Previous $69,000 1.45%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	BUY	$0.55 - $0.98 $23,566 - $41,992	42,849 Added 52.18%	124,967 $68,000
Q4 2024 Feb 12, 2025	BUY	$0.84 - $1.77 $7,550 - $15,910	8,989 Added 12.29%	82,118 $69,000
Q3 2024 Nov 12, 2024	BUY	$1.13 - $2.25 $15,616 - $31,095	13,820 Added 23.3%	73,129 $90,000
Q2 2024 Aug 09, 2024	BUY	$2.0 - $2.8 $9,084 - $12,717	4,542 Added 8.29%	59,309 $125,000
Q3 2023 Nov 13, 2023	BUY	$1.75 - $3.95 $7,430 - $16,771	4,246 Added 8.4%	54,767 $150,000
Q4 2022 Feb 13, 2023	SELL	$1.37 - $2.19 $138 - $221	-101 Reduced 0.2%	50,521 $72,000
Q3 2022 Nov 14, 2022	SELL	$2.16 - $3.33 $4,002 - $6,170	-1,853 Reduced 3.53%	50,622 $109,000
Q2 2022 Aug 12, 2022	SELL	$1.94 - $4.02 $117,507 - $243,495	-60,571 Reduced 53.58%	52,475 $136,000
Q1 2022 May 13, 2022	BUY	$3.19 - $6.17 $86,551 - $167,404	27,132 Added 31.58%	113,046 $452,000
Q4 2021 Feb 11, 2022	BUY	$5.21 - $7.93 $304,597 - $463,619	58,464 Added 212.98%	85,914 $489,000
Q3 2021 Nov 12, 2021	BUY	$7.07 - $14.84 $194,071 - $407,358	27,450 New	27,450 $214,000

Others Institutions Holding INDP

# of Institutions

Shares Held

687K

Call Options Held

Put Options Held

View Full List

About Indaptus Therapeutics, Inc.

Ticker INDP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 8,258,600
Market Cap $3.06M
Description
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B v...

More about INDP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Account

Geode Capital Management, LLC Indaptus Therapeutics, Inc. Transaction History